AstraZeneca to Recover Global Rights to Brazikumab From Allergan
January 27 2020 - 2:48AM
Dow Jones News
By Ian Walker
AstraZeneca PLC (AZN.LN) said Monday that it will take back the
global rights to brazikumab after ending a license deal with
Allergan PLC (AGN).
AstraZeneca said Allergen will fund the costs of developing
brazikumab, which is used for Crohn's disease and ulcerative
colitis.
The transaction is expected to complete in the first quarter of
this year, subject to regulatory approvals associated with AbbVie
Inc.'s (ABBV) proposed acquisition of Allergan, AstraZeneca
said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 27, 2020 02:33 ET (07:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
